Monday is the fourteenth day of an open letter from Australians for AI Safety asking the Australian Director of Biosecurity to mandate synthetic-nucleic-acid screening at the Biosecurity Import Conditions chokepoint. [1] It is also the fifteenth day of U.S. federal silence on a parallel mechanism, following the disbanding of the National Science Board. Two countries, one ocean, two different shapes of state capacity on the same week the Trump-Xi summit is three days out.

The paper's account of the divergence on May 10 framed the comparison as state-capacity, not policy. The Australian Biosecurity Act of 2015 already authorizes the Director to impose import conditions without primary legislation; the BICON permit system is the operative chokepoint. [2] The International Gene Synthesis Consortium — Twist Bioscience, IDT, and GenScript — already screens orders voluntarily. The petition is asking that the screen become a condition of import, not a vendor courtesy.

The U.S. side has the harder vacancy. The NSB disbanding on April 26 removed the federal advisory structure that would normally produce a counter-proposal. The Doudna-Esvelt-Collins essay in Science argues that an AI capable of designing novel pathogens is a foreseeable instrument, not a hypothetical one. [3] The chokepoint logic — screen the synthesis vendors, not the model weights — is the only currently deployable defense the synthesis-industry roadmap recognizes. Canberra is acting on a statute it already has. Washington is between statutes it no longer convenes a board to draft. The fourteen-day and fifteen-day clocks measure that gap.

-- DARA OSEI, London